Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 8/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.34 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30104080 | 0.85 | HTT (0.42) | HTTCRBNDDB1MGAMALDH1A1 | |
| SCHEMBL19542244 | 0.82 | CRBN (0.48) | HTTCRBNDDB1ALDH1A1MAPT | |
| SCHEMBL18940450 | 0.75 | CYP11B1 (0.35) | HTTMGAMALDH1A1MAPTP4HA1 | |
| SCHEMBL3515984 | 0.75 | NPC1 (0.35) | CRBNMAPTCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL14494384 | 0.75 | PDE3B (0.40) | CRBNMAPTCYP11B1CYP11B2 | |
| SCHEMBL16823586 | 0.75 | AHR (0.43) | CRBNDDB1ALDH1A1MAPTCYP11B1 | |
| SCHEMBL31714592 | 0.75 | CA9 (0.50) | HTTCRBNDDB1ALDH1A1MAPT | |
| SCHEMBL15530160 | 0.75 | AURKA (0.40) | CRBNDDB1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL22159524 | 0.74 | CRBN (0.57) | CRBNSMYD3 | |
| SCHEMBL29809267 | 0.74 | CRBN (0.57) | CRBNSMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333407-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-30 | — | — | US | disclosed |
| EP-2846804-B1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME (US) | 2017-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333407-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBG1, HBG2, HBB | HTT 898/4885CRBN 1425/4885DDB1 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.